Prosensa Holding N.V. (RNA) Reports Q3 Loss of EUR 0.29/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Prosensa Holding N.V. (RNA) Reports Q3 Loss of EUR 0.29/Share

Prosensa Announces 3rd Quarter 2014 Financial Results and Recent Corporate Developments

November 17, 2014 7:00 AM EST

Rolling NDA submission drisapersen underway EMA filing for conditional approval anticipated to follow NDA submission Re-dosing has commenced in United States, Belgium & Sweden Cash & cash equivalents at quarter-end 62M

LEIDEN, The Netherlands, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (Nasdaq: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today reported financial results for the third quarter ending September 30, 2014 and provided an update on the regulatory plans and re-dosing for drisapersen, our lead exon-skipping drug candidate, and... More